STOCK MARKET BSE NSE

Government allocates additional 29,250 vials of Amphotericin-B to states, UTs

Amphotericin-B is used to treat Mucormycosis, also known as Black Fungus, which damages the nose, eyes, sinuses, and sometimes even the brain.

Published: 26th May 2021 02:41 PM  |   Last Updated: 26th May 2021 02:46 PM   |  A+A-

Coronavirus, Vaccine

For representational purposes. (Photo | Vinay Madapu, EPS)

By PTI

NEW DELHI: The government has allocated 29,250 additional vials of Amphotericin-B drug to states and Union Territories, Union Minister for Chemicals and Fertilisers Sadananda Gowda said on Wednesday.

Amphotericin-B is used to treat Mucormycosis, also known as Black Fungus, which damages the nose, eyes, sinuses, and sometimes even the brain.

"Additional 29,250 vials of #Amphotericin- B drug, used in treatment of #Mucormycosis, have been allocated to all the States/UTs today. The allocation has been made based on the number of patients under treatment which is 11,717 across the country," Gowda tweeted.

The government has allocated 7,210 vials to Gujarat, followed by 6,980 vials to Maharashtra as part of the 29,250 fresh allocation.

Gujarat and Maharashtra currently lead in Mucormycosis infections in the country with 2,859 and 2,770 cases respectively.

Other states like Andhra Pradesh (1,930), Madhya Pradesh (1,910), Telangana (1,890), Uttar Pradesh (1,780), Rajasthan (1,250), Karnataka (1,220), Haryana (1,110) also received additional vials to counter the disease.

The government had allocated 19,420 vials of Amphotericin-B to various states, Union Territories (UTs) and Central Institutions on May 24.

Earlier on May 21, the government had allocated 23,680 vials of the drug to various states and Union Territories.

Mucormycosis is a very rare infection which is caused by exposure to mucor mould which is commonly found in soil, plants, manure, and decaying fruits and vegetables.

It affects the sinuses, the brain and the lungs and can be life-threatening in diabetic or severely immuno-compromised individuals such as cancer patients or people with HIV/AIDS.

The doctors in India are documenting an alarming number of cases of Mucormycosis among patients with COVID-19 and those who have recently recovered.

They believe that Mucormycosis may be triggered by the use of steroids, a life-saving treatment for severe and critically ill COVID-19 patients.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp